SAB Long Term Debt vs Short Long Term Debt Analysis

SABSW Stock

USD 0.07 0 4.43%

SAB Biotherapeutics financial indicator trend analysis is much more than just breaking down SAB Biotherapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether SAB Biotherapeutics is a good investment. Please check the relationship between SAB Biotherapeutics Long Term Debt and its Short Long Term Debt accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in SAB Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more information on how to buy SAB Stock please use our How to Invest in SAB Biotherapeutics guide.

Long Term Debt vs Short Long Term Debt

Long Term Debt vs Short Long Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of SAB Biotherapeutics Long Term Debt account and Short Long Term Debt. At this time, the significance of the direction appears to have pay attention.

The correlation between SAB Biotherapeutics' Long Term Debt and Short Long Term Debt is -0.76. Overlapping area represents the amount of variation of Long Term Debt that can explain the historical movement of Short Long Term Debt in the same time period over historical financial statements of SAB Biotherapeutics, assuming nothing else is changed. The correlation between historical values of SAB Biotherapeutics' Long Term Debt and Short Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Long Term Debt of SAB Biotherapeutics are associated (or correlated) with its Short Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Long Term Debt has no effect on the direction of Long Term Debt i.e., SAB Biotherapeutics' Long Term Debt and Short Long Term Debt go up and down completely randomly.

Correlation Coefficient

-0.76

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Long Term Debt

Long-term debt is a debt that SAB Biotherapeutics has held for over one year. Long-term debt appears on SAB Biotherapeutics balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on SAB Biotherapeutics balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Short Long Term Debt

The total of a company's short-term and long-term borrowings.

Most indicators from SAB Biotherapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into SAB Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in SAB Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more information on how to buy SAB Stock please use our How to Invest in SAB Biotherapeutics guide.At this time, SAB Biotherapeutics' Sales General And Administrative To Revenue is fairly stable compared to the past year. Enterprise Value Over EBITDA is likely to climb to 0.35 in 2024, whereas Tax Provision is likely to drop 0.00 in 2024.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	236.6K	3.3M	3.7M	3.9M
Interest Income	23.1K	71.1K	130.8K	80.1K

Depreciation And Amortization Interest Income

SAB Biotherapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital
Total Assets		-0.73	0.81	0.87	0.98	0.95	-0.87	-0.56	0.26	0.86	0.94	0.92	0.86	0.26	-0.95	-0.41	-0.32	0.83	0.88	0.69	0.98	0.96	-0.86	0.99	-0.65	0.86
Short Long Term Debt Total	-0.73		-0.66	-0.64	-0.71	-0.76	0.86	0.87	0.3	-0.85	-0.76	-0.93	-0.85	0.33	0.68	0.39	0.86	-0.54	-0.82	-0.51	-0.72	-0.82	0.52	-0.68	0.8	-0.74
Other Current Liab	0.81	-0.66		0.98	0.71	0.88	-0.64	-0.31	0.25	0.62	0.88	0.82	0.62	0.15	-0.78	-0.27	-0.24	0.96	0.57	0.88	0.7	0.84	-0.89	0.74	-0.37	0.52
Total Current Liabilities	0.87	-0.64	0.98		0.79	0.94	-0.66	-0.28	0.39	0.64	0.94	0.84	0.64	0.32	-0.87	-0.42	-0.18	0.95	0.6	0.82	0.79	0.89	-0.96	0.79	-0.37	0.59
Total Stockholder Equity	0.98	-0.71	0.71	0.79		0.93	-0.85	-0.57	0.3	0.83	0.93	0.9	0.83	0.32	-0.97	-0.52	-0.35	0.71	0.9	0.54	1.0	0.95	-0.81	0.96	-0.64	0.86
Property Plant And Equipment Net	0.95	-0.76	0.88	0.94	0.93		-0.76	-0.46	0.37	0.74	1.0	0.93	0.74	0.33	-0.98	-0.6	-0.36	0.83	0.78	0.64	0.93	0.99	-0.92	0.88	-0.5	0.72
Net Debt	-0.87	0.86	-0.64	-0.66	-0.85	-0.76		0.86	0.2	-1.0	-0.76	-0.91	-1.0	0.16	0.74	0.22	0.58	-0.66	-0.9	-0.64	-0.85	-0.82	0.61	-0.89	0.94	-0.96
Retained Earnings	-0.56	0.87	-0.31	-0.28	-0.57	-0.46	0.86		0.59	-0.86	-0.46	-0.74	-0.86	0.54	0.43	0.12	0.86	-0.26	-0.81	-0.31	-0.58	-0.57	0.18	-0.59	0.95	-0.78
Accounts Payable	0.26	0.3	0.25	0.39	0.3	0.37	0.2	0.59		-0.21	0.36	0.0	-0.21	0.98	-0.46	-0.53	0.6	0.28	-0.08	0.01	0.3	0.26	-0.56	0.2	0.49	-0.06
Cash	0.86	-0.85	0.62	0.64	0.83	0.74	-1.0	-0.86	-0.21		0.74	0.9	1.0	-0.17	-0.73	-0.22	-0.57	0.65	0.88	0.63	0.83	0.8	-0.6	0.88	-0.94	0.97
Non Current Assets Total	0.94	-0.76	0.88	0.94	0.93	1.0	-0.76	-0.46	0.36	0.74		0.93	0.74	0.32	-0.98	-0.6	-0.37	0.82	0.79	0.64	0.93	0.99	-0.92	0.87	-0.5	0.72
Long Term Debt	0.92	-0.93	0.82	0.84	0.9	0.93	-0.91	-0.74	0.0	0.9	0.93		0.9	-0.02	-0.88	-0.46	-0.63	0.75	0.89	0.65	0.9	0.96	-0.76	0.87	-0.75	0.83
Cash And Short Term Investments	0.86	-0.85	0.62	0.64	0.83	0.74	-1.0	-0.86	-0.21	1.0	0.74	0.9		-0.17	-0.73	-0.22	-0.57	0.65	0.88	0.63	0.83	0.8	-0.6	0.88	-0.94	0.97
Net Receivables	0.26	0.33	0.15	0.32	0.32	0.33	0.16	0.54	0.98	-0.17	0.32	-0.02	-0.17		-0.45	-0.54	0.62	0.21	-0.06	-0.06	0.32	0.23	-0.51	0.22	0.42	0.01
Common Stock Shares Outstanding	-0.95	0.68	-0.78	-0.87	-0.97	-0.98	0.74	0.43	-0.46	-0.73	-0.98	-0.88	-0.73	-0.45		0.66	0.29	-0.75	-0.79	-0.53	-0.96	-0.97	0.9	-0.89	0.48	-0.75
Non Current Liabilities Total	-0.41	0.39	-0.27	-0.42	-0.52	-0.6	0.22	0.12	-0.53	-0.22	-0.6	-0.46	-0.22	-0.54	0.66		0.27	-0.14	-0.31	0.16	-0.52	-0.57	0.52	-0.29	0.05	-0.3
Capital Lease Obligations	-0.32	0.86	-0.24	-0.18	-0.35	-0.36	0.58	0.86	0.6	-0.57	-0.37	-0.63	-0.57	0.62	0.29	0.27		-0.06	-0.62	-0.09	-0.36	-0.47	0.02	-0.28	0.67	-0.43
Other Current Assets	0.83	-0.54	0.96	0.95	0.71	0.83	-0.66	-0.26	0.28	0.65	0.82	0.75	0.65	0.21	-0.75	-0.14	-0.06		0.55	0.95	0.7	0.78	-0.9	0.79	-0.4	0.59
Other Stockholder Equity	0.88	-0.82	0.57	0.6	0.9	0.78	-0.9	-0.81	-0.08	0.88	0.79	0.89	0.88	-0.06	-0.79	-0.31	-0.62	0.55		0.47	0.91	0.87	-0.53	0.9	-0.8	0.85
Total Liab	0.69	-0.51	0.88	0.82	0.54	0.64	-0.64	-0.31	0.01	0.63	0.64	0.65	0.63	-0.06	-0.53	0.16	-0.09	0.95	0.47		0.53	0.61	-0.72	0.69	-0.46	0.53
Net Invested Capital	0.98	-0.72	0.7	0.79	1.0	0.93	-0.85	-0.58	0.3	0.83	0.93	0.9	0.83	0.32	-0.96	-0.52	-0.36	0.7	0.91	0.53		0.95	-0.8	0.96	-0.64	0.86
Property Plant And Equipment Gross	0.96	-0.82	0.84	0.89	0.95	0.99	-0.82	-0.57	0.26	0.8	0.99	0.96	0.8	0.23	-0.97	-0.57	-0.47	0.78	0.87	0.61	0.95		-0.85	0.9	-0.58	0.76
Short Long Term Debt	-0.86	0.52	-0.89	-0.96	-0.81	-0.92	0.61	0.18	-0.56	-0.6	-0.92	-0.76	-0.6	-0.51	0.9	0.52	0.02	-0.9	-0.53	-0.72	-0.8	-0.85		-0.79	0.31	-0.62
Total Current Assets	0.99	-0.68	0.74	0.79	0.96	0.88	-0.89	-0.59	0.2	0.88	0.87	0.87	0.88	0.22	-0.89	-0.29	-0.28	0.79	0.9	0.69	0.96	0.9	-0.79		-0.7	0.89
Capital Stock	-0.65	0.8	-0.37	-0.37	-0.64	-0.5	0.94	0.95	0.49	-0.94	-0.5	-0.75	-0.94	0.42	0.48	0.05	0.67	-0.4	-0.8	-0.46	-0.64	-0.58	0.31	-0.7		-0.9
Net Working Capital	0.86	-0.74	0.52	0.59	0.86	0.72	-0.96	-0.78	-0.06	0.97	0.72	0.83	0.97	0.01	-0.75	-0.3	-0.43	0.59	0.85	0.53	0.86	0.76	-0.62	0.89	-0.9

Click cells to compare fundamentals

SAB Biotherapeutics Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for SAB Stock Analysis

When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

SAB Long Term Debt vs Short Long Term Debt Analysis

Long Term Debt vs Short Long Term Debt

Long Term Debt vs Short Long Term Debt Correlation Analysis

Correlation Coefficient

Long Term Debt

Short Long Term Debt

SAB Biotherapeutics fundamental ratios Correlations

SAB Biotherapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for SAB Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Invested Capital	+ 1.0	Total Stockholder Equity
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 0.99	Total Assets
Property Plant And Equipment Gross	+ 0.99	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 0.99	Non Current Assets Total

Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Common Stock Shares Outstanding	- 0.98	Non Current Assets Total
Common Stock Shares Outstanding	- 0.98	Property Plant And Equipment Net
Property Plant And Equipment Gross	- 0.97	Common Stock Shares Outstanding
Common Stock Shares Outstanding	- 0.97	Total Stockholder Equity